CLDN18.2 and 4-1BB Bispecific Antibody Givastomig Exerts Antitumor Activity Through CLDN18.2-expressing Tumor-Directed T-cell Activation
JOURNAL FOR IMMUNOTHERAPY OF CANCER(2023)
Key words
Immunotherapy,Tumor Microenvironment,Tumor-Infiltrating Lymphocytes
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined